- May 6, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Simponi Aria, Simponi
Synonyms :
golimumab
Class :
Antipsoriatics
Dosage Forms & Strengths
subcutaneous solution
50mg/0.5mL
100mg/1mL
IV solution
50mg/4mL
50 mg subcutaneous (SC) every Month
Or
2 mg/kg IV at weeks 0 and week 4, then every 8Weeks
50
mg
Subcutaneous (SC)
every month
Or
2 mg/kg IV at weeks 0 and 4, then every 8Weeks
Week 0: 200 mg SC
Week 2: 100 mg subcutaneous (SC); may be increased to 100 mg subcutaneous (SC)every 4 weeks.
Week 0: 200 mg SC
Week 2: 100 mg subcutaneous (SC); may be increased to 100 mg subcutaneous (SC)every 4 weeks.
Dosage Forms & Strengths
IV solution
50mg/4mL
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
it increases the adverse effects caused due to eptinezumab
golimumab exerts an antagonistic pharmacodynamic effect on the live rotavirus oral vaccine, leading to a reduction in its efficacy
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of vinblastine
when both drugs are combined, the metabolism of paclitaxel increases when compared with golimumab
when both the drugs are combined, the metabolism of carmustine increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
in combination with ofatumumab, golimumab increases the risk of adverse events
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
interaction raises immunosuppressive effects and risk of infection
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of certolizumab pegol
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
both the drugs increase the effect of immunosuppression risk of infection increases on administering both the drugs simultaneously
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
It may enhance the adverse effects when combined with sotrovimab
high risk of severe infection due to immunosuppression
Adverse drug reactions
Frequency Defined
>10%
Upper respiratory tract infection (12%)
1-10%
Bronchitis (2%)
Constipation (1%)
Injection site reactions
Increased ALT (4%)
Increased AST (3%)
Superficial fungal infections (2%)
Viral infections (5%)
Dizziness (2%)
Paresthesia (2%)
Sinusitis (2%)
Pregnancy warnings:
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned.
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: golimumab
Why do we use golimumab?
golimumab is an Antipsoriatics used to treat Rheumatoid Arthritis.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
